临床试验/NCT04001231

NCT04001231撤回1 期

A Phase 1, Open-Label Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety, and Tolerability of Exenatide Once-Weekly Suspension in Chinese Patients With Type 2 Diabetes Mellitus

AstraZeneca0 个研究点开始时间: 2020年6月30日最近更新: 2020年6月4日

适应症

干预措施

试验速览

阶段: 1 期
状态: 撤回
发起方: AstraZeneca
主要终点: AUC(0-8h)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to evaluate the pharmacokinetics, tolerability, and safety of single and multiple doses of exenatide once-weekly suspension via subcutaneous (SC) injection using a pre-filled, single-dose autoinjector in male and female Chinese with type 2 diabetes.

详细描述

This is an open-label, single- and multiple-dose, PK study in Chinese subjects with type 2 diabetes mellitus. Up to 30 patients may initially be enrolled to target at least 20 patients completing the study. Up to 10 more patients (ie, 40 in total) may be subsequently recruited to replace patients who discontinue, provided such discontinuations are not due to significant (based on PI and Sponsor judgment) safety or tolerability issues. Eligible patients will receive their first 2.0-mg dose of exenatide once-weekly suspension via subcutaneous (SC) injection using a pre-filled, single-dose autoinjector at Visit 3 (Day 1).Blood samples will be drawn for up to 168 hours after the first dose on Day 1 to assess single-dose PK for exenatide once-weekly suspension. Patients will receive the second dose of the investigational product (IP) at Visit 6 (Day 8). Thereafter, patients will receive weekly (±1 day) doses of IP up to Visit 18 (Week 14). Intensive and extended PK sampling will be conducted after administration of the final dose (Dose 14) to assess multiple-dose PK for exenatide once-weekly suspension. Follow-up observations will be conducted at Visits 22 to 29 (Weeks 15 to 26), with the final follow-up at/after Visit 29 (Week 26 ±2 days). During follow-up period, Blood samples will be collected for PK analyses. Subjects will be monitored closely for adverse events throughout the study.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Other
盲法: None

盲法说明

Open-label Study

入排标准

年龄范围: 20 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Provision of informed consent prior to any study-specific procedures.
•Male or female patients with T2DM treated with diet modification and exercise alone or in combination with a stable (in PI's opinion) regimen of metformin only for at least two months prior to screening. The T2DM diagnosis will be confirmed clinically by the PI, and should be consistent with the World Health Organization criteria for diagnosis and classification of diabetes
•Between 20 to 75 years of age inclusive at Visit 1 (Screening)
•The following criterion applies to females of child-bearing potential (not surgically sterilized and between menarche and 1-year postmenopause) only:
•Test negative for pregnancy at the time of screening.
•Intend not to become pregnant during the study.
•Are sexually inactive or have practiced a reliable method of birth control (for example, use of oral contraceptives or levonorgestrel, diaphragms with contraceptive jelly, cervical caps with contraceptive jelly, condoms with contraceptive foam, intrauterine devices, partner with vasectomy) for at least 6 weeks prior to screening.
•Agree to continue to use a reliable method of birth control (as determined by the PI) during the study and until 90 days after last dose.
•Have a body weight of ≥45 kg and a body mass index (BMI) of 18.5 to 35 kg/m2 inclusive at Visit 1 (Screening).
•Have clinical laboratory test results within the normal reference range for the population or study site, or with abnormalities deemed clinically insignificant by the PI. Abnormalities of plasma glucose (fasting ≤12.0 mmol/L and anytime≤15.0mmol/L), HbA1c (<10.5%), plasma lipids (TG<5.7 mmol/L), and urinary protein (with a range of trace < 2+ on dipstick) are acceptable.
•Venous access sufficient to allow blood sampling as per the protocol.
•Are reliable and willing to be available for the duration of the study and are willing to follow study procedures.

排除标准

•Involvement in the planning and/or conduct of the study (applies to bothAstraZeneca staff and/or staff at the study site, and direct family members).
•Previous enrollment in the present study or have previously completed or withdrawn from any other study investigating exenatide.
•Within 30 days of the initial dose of IP, have received treatment with a drug that has not received regulatory approval for any indication.
•Known allergy or hypersensitivity to exenatide or any of the excipients contained in these agents (exenatide: sodium acetate buffer, mannitol, metacresol, MCT vehicle).
•Previous treatment with exenatide or related GLP-1 receptor agonist compounds.
•History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.
•Systolic blood pressure (SBP) persistently (on ≥2 separate occasions) >160 mmHg on stable regimen of antihypertensive medication or >180 mmHg regardless of antihypertensive treatment.
•History of, or currently have angina, revascularization, myocardial infarction, or heart failure.
•Clinically significant peripheral vascular disease.
•Evidence of poorly controlled T2DM or evidence of significant diabetes-related complications such as:
•Plasma glucose >12 mmol/L (fasting) or >15 mmol/L (anytime) at Visit 1 (Screening)
•HbA1c >10.5%
•History of hypoglycemic or hyperglycemic coma within 1 year prior to Visit 1 (Screening)
•History of active diabetic proliferative retinopathy or macular oedema
•Known significant autonomic neuropathy as evidenced by urinary retention, orthostatic hypotension, diabetic diarrhea, or gastroparesis
•Two or more episodes of major hypoglycemia within 6 months prior to Visit 1 (Screening). See Section 5.2.8.1 for hypoglycemia classification.
•Impaired renal function (serum creatinine >125 μ/mol/L in women, >132 μ/mol/L in men).
•Liver disease, acute or chronic hepatitis, alanine aminotransferase (ALT/SGPT), or aspartate aminotransferase (AST) ≥3x upper limit of normal (ULN) of the reference range and total bilirubin level (TBL) ≥2xULN.
•Evidence of hepatitis B and/or positive hepatitis B surface antigen.
•Clinical symptoms associated with cholelithiasis (eg, cholecystitis or biliary colic), within 3 years of Visit 1 (Screening).
•History of, or currently have acute or chronic pancreatitis, or have triglyceride concentrations ≥500 mg/dL at Visit 1 (Screening).
•Have a serum calcitonin concentration ≥40 pg/mL at Visit 1 (Screening).
•An abnormality in the 12-lead ECG that, in the opinion of the PI, increases the risks associated with participating in the study.
•Evidence of significant active neuropsychiatric disease.
•Evidence of current use of drugs of abuse or history of use within the past year.
•Women who are lactating and/or breastfeeding.
•Use of over-the-counter or prescription medication (other than thyroid replacement therapy, metformin, antihypertensive medication, lipid-lowering agents, aspirin, or paracetamol/acetaminophen) 7 and 14 days, respectively prior to dosing. If this situation arises, inclusion of an otherwise suitable patient may occur if permitted by the PI and Sponsor.
•Significant active hematological disease and/or blood donation of more than 400 mL within the last 6 months.
•An average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or patients unwilling to adhere to study alcohol restrictions (1 unit=360 mL of beer; 150 mL of wine; 45 mL of distilled spirits).
•A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B.
•Currently enrolled in any other clinical study.
•Determined by the PI to be unsuitable for inclusion in this study.

研究组 & 干预措施

Single arm of exenatide once-weekly suspension

Experimental

Exenatide once-weekly suspension via subcutaneous (SC) injection

干预措施: Exenatide Once-Weekly Suspension (Drug)

结局指标

主要结局

AUC(0-8h)

时间窗: Blood sample will be collected on Visit 3-6 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 7-17 (pre-dose). Visit 18-22 (pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 24, 72, 120, 168 hours post-dose). Visit 23-29 (once/visit).

Area under the plasma concentration-time curve from zero (pre-dose) to time 8 h calculated by linear up/log down trapezoidal rule (following the first dose on Day 1)

AUC(0-168h)

Area under the plasma concentration-time curve from zero (pre-dose) to time 168 h calculated by linear up/log down trapezoidal rule (following the first dose on Day 1)

AUCτ,ss

Area under the plasma concentration-time curve over a dosing interval at steady state calculated by linear up/log down trapezoidal rule (following administration at Week 14)

Plasma concentrations versus time profile of exenatide

To evaluate the PK of single and multiple doses of exenatide once-weekly suspension in native Chinese patients with T2DM

CL/F

Apparent total body clearance (L/h) calculated as dose/AUCτ,ss (following administration at Week 14)

Cmax

Maximum plasma concentration directly from the observed concentration versus time data

Vss/F

Apparent volume of distribution at steady state (following administration at Week 14)

tmax

Time of maximum plasma concentration

Cav,ss

Average plasma concentration at steady state calculated as AUCτ ,ss/τ (following administration at Week 14)

Rac

Accumulation ratio calculated as AUCτ,ss/AUC0-168h

t½

Apparent terminal half-life (h) determined as ln 2/λ z (following administration at Week 14)

λ z

Apparent terminal elimination rate constant (1/h) determined by linear regression of the terminal points of the log-linear concentration-time curve. Visual assessment will be used to identify the terminal linear phase of the concentration-time profile. A minimum of 3 data points and an Rsq of at least 0.800 will be used for determination. (following administration at Week 14)

Ctrough

Trough plasma concentrations through the treatment period will be evaluated graphically to assess steady-state attainment

次要结局

Blood pressure (BP)(Blood pressure will be collected at Visit 1, Visit 3 (pre-dose, 2- and 24-hours post-dose), Visit 4 (post-dose), Visit 5 (post-dose), Visit 6-17 (pre-dose), Visit 18 (pre-dose, 2- and 24-hours post-dose), Visit 19-21 (post-dose), Visit 22-29)
Electrocardiograms (ECGs)(ECGs will be performed at Visit 1 (screening), Visit 3 (Day 1, pre-dose and 2 hours post-dose), Visit 18 (Week 14, Day 1, pre-dose and 2 hours post-dose) and Visit 29 (Week 26, follow-up))
Safety and tolerability as determined by abnormality in urinalysis compared to baseline.(Blood sample will be collected at Visit 1 (screening), Visit 2 (admission, day -1), Visit 6 (Week2, pre-dose), Visit 8 (Week4, pre-dose), Visit 17 (Week13, pre-dose), Visit 23 (Week16, follow-up), Visit 29 (Week26, follow-up))
Fasting blood glucose(Blood sample will be collected at Visit1, Visit3 (Day1, pre-dose), Visit4-5 (Day4, Day6, post-dose), Visit6-18 (Week2-14, pre-dose), Visit19 (Week14, Day4, post-dose) and Visit20 (Week14, Day6, post-dose), Visit22-26 (Week15-20) and Visit29 (Week26))
Calcitonin(Blood sample will be collected at Visit1 (screening), Visit21 (Week14, Day7) and Visit29 (Week26, follow-up))
Pulse rate(Pulse rate will be collected at Visit 1, Visit 3 (pre-dose, 2- and 24-hours post-dose), Visit 4 (post-dose), Visit 5 (post-dose), Visit 6-17 (pre-dose), Visit 18 (pre-dose, 2- and 24-hours post-dose), Visit 19-21 (post-dose), Visit 22-29)
Body temperature(Body temperature will be collected at Visit 1, Visit 3 (pre-dose, 2- and 24-hours post-dose), Visit 4 (post-dose), Visit 5 (post-dose), Visit 6-17 (pre-dose), Visit 18 (pre-dose, 2- and 24-hours post-dose), Visit 19-21 (post-dose), Visit 22-29)
Safety and tolerability as determined by abnormality in clinical chemistry compared to baseline.(Blood sample will be collected at Visit 1 (screening), Visit 2 (admission, day -1), Visit 6 (Week2, pre-dose), Visit 8 (Week4, pre-dose), Visit 17 (Week13, pre-dose), Visit 23 (Week16, follow-up), Visit 29 (Week26, follow-up))
Safety and tolerability as determined by abnormality in hematology compared to baseline.(Blood sample will be collected at Visit 1 (screening), Visit 2 (admission, day -1), Visit 6 (Week2, pre-dose), Visit 8 (Week4, pre-dose), Visit 17 (Week13, pre-dose), Visit 23 (Week16, follow-up), Visit 29 (Week26, follow-up))
Number of subjects with adverse events(Adverse event will be collected from Visit 1 (screening) to Visit 29 (Week 26, follow-up).)
The presence and titer of anti-exenatide antibodies(Visit 3, Visit 6~18, Visit 21 and Visit 29 (once every visit))

研究者

发起方

AstraZeneca

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

1 期

Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532HealthyType 2 Diabetes Mellitus

NCT01369602Pfizer27

已完成

1 期

Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy SubjectsHepatic Impairment

NCT02683577Ipsen24

已完成

1 期

A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic FunctionHepatic Impairment

NCT01631097AVEO Pharmaceuticals, Inc.44

已完成

1 期

TMC435 HPC1004 - Phase I Study Investigating the Pharmacokinetics of TMC435 in Healthy Chinese VolunteersHepatitis C

NCT01224197Tibotec Pharmaceuticals, Ireland32

已完成

1 期

Desidustat in the Treatment of Chemotherapy Induced AnemiaAnemia of Chronic Kidney DiseaseChemotherapy Effect

NCT04667533Zydus Lifesciences Limited24